Skip to content

World-first psilocybin clinical trial in the treatment of Generalised Anxiety Disorder receives ethics approval

By Gold Cross - October 28, 2021

Psilocybin
This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

New STI impacts 1 in 3 women: landmark study reveals men are the missing link

Gold Cross | March 10, 2025

CTE funding set to boost Australia’s future brain health

Gold Cross | February 21, 2025

What’s the difference between period pain and endometriosis pain?

Gold Cross | February 19, 2025
Pharmacist Only

National spotlight on healthy ageing and social connection to reduce heart healthcare burden this February

Gold Cross | February 11, 2025
BD Rowa automation gives you back 6 hours in your day

Latest Posts

Pharmacist Only
Unstoppable and spared from impacts of Ex-Tropical Cyclone Alfred: APP2025 to go ahead as planned
Gold Cross | March 10, 2025
New STI impacts 1 in 3 women: landmark study reveals men are the missing link
Gold Cross | March 10, 2025
Pharmacist Only
Two weeks until APP2025 brings the pharmacy industry together on the Gold Coast
Gold Cross | March 6, 2025

Featured Posts

GOLD CROSS endorses Team Medical®
Gold Cross | February 18, 2025
College training supports new Australian Government women’s health initiative
Gold Cross | February 10, 2025
Professor Anna Peeters appointed VicHealth CEO
Gold Cross | February 4, 2025

Tags

Scroll To Top